Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Fatty Liver » Non-alcoholic Fatty Liver Disease
Description
Fatty liver finding without excessive ALCOHOL CONSUMPTION. MeSH
Hierarchy View
Phase 4 Indicated Drugs (38)
Phase 3 Indicated Drugs (35)
Phase 2 Indicated Drugs (130)
Phase 1 Indicated Drugs (50)
Other Experimental Indicated Drugs (65)
Organization Involved with Phase 4 Indications (65)
All India Institute of Medical Sciences
Belupo d.d., Koprivnica, Croatia
Clinical Hospital Centre Rijek, Croatia
Federal Ministry of Health, Germany
Huntington Medical Research Institutes
Kuhnil Pharmaceutical Co., Ltd.
People's Liberation Army of China
Second Military Medical University
The Deutsche Diabetes Forschungsgesellschaft e.V.
Organization Involved with Phase 3 Indications (40)
Organization Involved with Phase 2 Indications (184)
American College of Gastroenterology
Antipodean Pharmaceuticals, Inc.
Aristotle University of Thessaloniki
Association pour la Recherche sur les Maladies Hépatiques Virales
Beilinson Hospital, Petach Tikva
Case Western Reserve University
Gottfried Wilhelm Leibniz Universität Hannover
Guangdong Raynovent Biotech Co., Ltd
Holy Family Hospital, Nazareth, Israel
Kashan University of Medical Sciences
KTH Royal Institute of Technology
Medical University of Bialystok
Mochida Pharmaceutical Company, Ltd.
Moorgreen Hospital, Southampton
Nanyang Technological University
National Institute of Allergy and Infectious Diseases (NIAID)
National University of Singapore
Pediatric Municipal Hospital of Rzeszow, Poland
Queen Elizaberth Hospital, Sabah
Radiological Society of North America
Sahlgrenska University Hospital, Sweden
Shanghai Municipal Science and Technology Commission
Silesian University of Medicine
Singapore Bioimaging Consortium
Singapore Clinical Research Institute
Singapore Institute for Clinical Sciences
State Novosibirsk Regional Clinical Hospital
St. Petersburg State Public Medical Institution
Sultanah Bahiyah Hospital, Alor Star
Tengku Ampuau Afzan Hospital, Kuantan
University of California, San Diego
University of California, San Francisco
University of Illinois at Chicago
University of North Carolina at Chapel Hill
University of Texas at Houston
Organization Involved with Phase 1 Indications (31)
Organization Involved with Other Experimental Indications (56)
Bogomolets National Medical University
Canadian Institutes of Health Research (CIHR)
Children's Hospital Los Angeles
CIHR Canadian HIV Trials Network
Cumberland Research Associates
Daiwa Pharmaceutical Corporation
Danish Council for Independent Research
Eurasia Invest Ltd., Kazakhstan
Federal University of Health Science of Porto Alegre
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
